Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Vivek, Ruhela"'
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 16, Iss 7, Pp PC22-PC26 (2022)
Introduction: Timely intervention in patients of obstructive uropathy secondary to renal and/or ureteric stones can reduce the morbidity and mortality in such patients. Aim: To determine the factors predicting recovery in patients of urinary stones
Externí odkaz:
https://doaj.org/article/b407e1466da44ba19d447b1e610db032
Publikováno v:
Frontiers in Bioinformatics, Vol 2 (2022)
In eukaryotic cells, miRNAs regulate a plethora of cellular functionalities ranging from cellular metabolisms, and development to the regulation of biological networks and pathways, both under homeostatic and pathological states like cancer.Despite t
Externí odkaz:
https://doaj.org/article/fe20339b1da44b7ab2175c6e06fc3196
Autor:
Gurvinder Kaur, Ritu Gupta, Krishnamachari Sriram, Ajay Gogia, Lalit Kumar, Atul Sharma, Anubha Gupta, Lata Rani, Vivek Ruhela
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 1, Pp 1-9 (2020)
Blood Cancer Journal
Blood Cancer Journal
Abnormal expression patterns of regulatory small non-coding RNA (sncRNA) molecules such as microRNAs (miRs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs) play an important role in the development and progression of cancer. Ident
Autor:
Sishir, Gang, Prakash, Khetan, Deepak, Varade, Venkata Ramakrishna, Chinta, Siddharth, Mavani, Umesh, Gupta, S Venkata Krishna, Reddy, Sunil, Rajanna, Tarun, Jeloka, Vivek, Ruhela, Kevinkumar, Kansagra, Pooja, Kanani, Jayesh, Bhatt, Kuldipsinh, Zala
Publikováno v:
American journal of nephrology. 53(5)
A phase 3 study to assess the efficacy and safety of the desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, against the epoetin alfa for the treatment of anemia in patients with chronic kidney disease (CKD) with dialysis depen
Autor:
Dhananjai, Agrawal, Deepak, Varade, Hardik, Shah, Alm, Nazar, Jayakumar, Krishnan, Vineet, Shukla, Chinta, Ramakrishna, Mahel Chinthana, Bandara Galahitiyawa, Sidhharth B, Mavani, Sunil, Rajanna, Petkar, Jikki, Shamila, De Silva, Vivek, Ruhela, Parshottam, Koradia, Kevinkumar, Kansagra, Pooja, Kanani, Nitin, Sharma, Kuldipsinh, Zala, Deven, Parmar
Publikováno v:
American journal of nephrology. 53(5)
Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being developed to treat anemia in patients with chronic kidney disease (CKD) without dialysis dependency.In total, 588 patients with a clinical diagnosis of anemia due to
Autor:
Akanksha, Farswan, Anubha, Gupta, Lingaraja, Jena, Vivek, Ruhela, Gurvinder, Kaur, Ritu, Gupta
Publikováno v:
Am J Cancer Res
Mutational Signatures and Tumor mutational burden (TMB) have emerged as prognostic biomarkers in cancer genomics. However, the association of TMB with overall survival (OS) is still unknown in newly diagnosed multiple myeloma (NDMM) patients. Further
Autor:
Vishal, Thakker, Prashant, Sarda, Vivek, Ruhela, Manali, Arora, Rohit, Sharma, Rajiv Kumar, Azad
Publikováno v:
Indian Journal of Nephrology. 32:452
Arteriovenous fistulas (AVFs) are the preferred route of hemodialysis in end-stage renal disease. However, recurrent patency loss is an obstacle in long-term maintenance. Endovascular treatments may provide a durable option for prolongation of patenc
Autor:
Ritu Gupta, Krishnamachari Sriram, Akanksha Farswan, Gurvinder Kaur, Vivek Ruhela, Anubha Gupta
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S57
Background Multiple Myeloma (MM) is preceded by the premalignant stage of Monoclonal Gammopathy of Undetermined Significance (MGUS) and therefore, it is important to identify the genetic factors responsible for progression of MGUS to MM. We have buil
Publikováno v:
Indian Journal of Pharmacology
Autor:
S Mohendra, Sukanta Barai, Awadhesh Kumar, Vivek Ruhela, Anupma Kaul, Narayan Prasad, Vikas Agarwal, R.K. Sharma, Annapurna Gupta, Dharmendra Bhadauria
Publikováno v:
Indian Journal of Medical Microbiology, Vol 33, Iss 3, Pp 447-452 (2015)
Seronegative Invasive Gastro-intestinal cytomegalovirus disease in renal allograft recipients Background -CMV as oppurtunistic infection affecting the gastrointerstinal tract is the most common cause for tissue invasive CMV disease occuring in 10-30%